ATYR

ATYR PHARMA, INC.

ATYR · CIK 1339970 · Annual (10-K) · Last 8 years

Financial Trends

Revenue$0M
20172024
Net Income−$64M
20172024
Operating CF−$69M
20172024
Free Cash Flow−$69M
20172024

Income Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Revenue$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B——
Cost of Revenue————————
Gross Profit————————
R&D Expense$0.1B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
SG&A Expense————————
Operating Income$-0.1B$-0.1B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B
Net Income$-0.1B$-0.1B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B
EPS (Basic)$-0.86$-0.94$-1.60—————
EPS (Diluted)$-0.86$-0.94$-1.60—————

Balance Sheet

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Total Assets$0.1B$0.1B$0.1B$0.1B$0.0B$0.0B$0.1B$0.1B
Current Assets$0.1B$0.1B$0.1B$0.1B$0.0B$0.0B$0.1B$0.1B
Cash & Equivalents$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Total Liabilities————————
Current Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$0.1B$0.1B$0.1B$0.1B$0.0B$0.0B$0.0B$0.1B

Cash Flow Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Operating Cash Flow$-0.1B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B—
Investing Cash Flow$0.0B$-0.0B$0.0B$-0.1B$0.0B$0.0B$0.0B—
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.0B$0.1B$0.0B$0.1B$0.0B$0.0B$-0.0B—
← Companies